Wendy Watson

4.5k total citations · 2 hit papers
59 papers, 3.3k citations indexed

About

Wendy Watson is a scholar working on Epidemiology, Microbiology and Sociology and Political Science. According to data from OpenAlex, Wendy Watson has authored 59 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Epidemiology, 11 papers in Microbiology and 6 papers in Sociology and Political Science. Recurrent topics in Wendy Watson's work include Pneumonia and Respiratory Infections (35 papers), Respiratory viral infections research (24 papers) and Pneumocystis jirovecii pneumonia detection and treatment (17 papers). Wendy Watson is often cited by papers focused on Pneumonia and Respiratory Infections (35 papers), Respiratory viral infections research (24 papers) and Pneumocystis jirovecii pneumonia detection and treatment (17 papers). Wendy Watson collaborates with scholars based in United States, Germany and Japan. Wendy Watson's co-authors include Ih Chang, Henry R. Shinefield, Kathryn M. Edwards, Steven Black, Jill Hackell, Robert Kohberger, Frank Malinoski, Kathleen Ensor, Paula Ray and George R. Siber and has published in prestigious journals such as SHILAP Revista de lepidopterología, PEDIATRICS and Clinical Infectious Diseases.

In The Last Decade

Wendy Watson

58 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children

2000 1.8k citations Steven Black, Henry R. Shinefield et al. The Pediatric Infectious Disease Journal profile →
Preterm birth: Case definition & guidelines for data collection, analysis, and presentation of immunisation safety data

2016 300 citations Flor M. Muñoz, Bernard Gonik et al. Vaccine profile →

Peers

Countries citing papers authored by Wendy Watson

Since Specialization

Citations

This map shows the geographic impact of Wendy Watson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wendy Watson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wendy Watson more than expected).

Fields of papers citing papers by Wendy Watson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wendy Watson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wendy Watson. The network helps show where Wendy Watson may publish in the future.

Co-authorship network of co-authors of Wendy Watson

This figure shows the co-authorship network connecting the top 25 collaborators of Wendy Watson. A scholar is included among the top collaborators of Wendy Watson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wendy Watson. Wendy Watson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Immunogenicity and safety of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine–naive adults ≥18 years of age in India: A phase 3 single-arm trial 2026 ·Human Vaccines & Immunotherapeutics ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Annaliesa S. Anderson, Kara Bickham, Wendy Watson, (unknown)	0
2	A phase 3 randomized study to evaluate safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in healthy Japanese infants 2024 ·International Journal of Infectious Diseases ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Yahong Peng, (unknown), Peter C. Giardina, (unknown), William C. Gruber, Wendy Watson	2
3	A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan 2024 ·Vaccine ·Miwa Haranaka, Joon Young Song, Kuo‐Chin Huang, (unknown), (unknown), (unknown), (unknown), (unknown), Yahong Peng, Ingrid L. Scully, (unknown), William C. Gruber, Daniel A. Scott, Wendy Watson	6
4	Intergenerational Connections: US College Students’ Attitudes and Expectations Toward Older Adults and Aging in an Online Critical Community Engagement Project 2024 ·SHILAP Revista de lepidopterología ·Sandra L. Faulkner, (unknown), (unknown), Wendy Watson	2
5	Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults ≥65 years old 2023 ·Vaccine ·David Fitzpatrick, (unknown), Kari Yacisin, (unknown), Todd Belanger, (unknown), Yahong Peng, (unknown), William C. Gruber, Daniel A. Scott, Wendy Watson	13
6	Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: A phase 3 randomized trial 2023 ·Vaccine ·Kevin Cannon, José F. Cardona, Kari Yacisin, Allison Thompson, Todd Belanger, (unknown), Yahong Peng, (unknown), John Ginis, William C. Gruber, Daniel A. Scott, Wendy Watson	12
7	Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease 2022 ·Human Vaccines & Immunotherapeutics ·Charu Sabharwal, Vani Sundaraiyer, Yahong Peng, (unknown), Todd Belanger, Bradford D. Gessner, Luis Jódar, Kathrin U. Jansen, William C. Gruber, Daniel A. Scott, Wendy Watson	2
8	Streptococcus pneumoniae serotype 15B polysaccharide conjugate elicits a cross-functional immune response against serotype 15C but not 15A 2022 ·Vaccine ·Hao Li, Michelle M. Kuttel, Neil Ravenscroft, Allison Thompson, A. Krishna Prasad, (unknown), Charles Y. Tan, David Cooper, Wendy Watson, Paul Liberator, Michael W. Pride, Kathrin U. Jansen, Annaliesa S. Anderson, Ingrid L. Scully	24
9	A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age 2021 ·Human Vaccines & Immunotherapeutics ·Brandon Essink, James T. Peterson, Kari Yacisin, Himal Lal, (unknown), Xia Xu, Ingrid L. Scully, Daniel A. Scott, William C. Gruber, Kathrin U. Jansen, Wendy Watson	2
10	A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age 2021 ·Vaccine ·Nicola P. Klein, Paula Peyrani, Kari Yacisin, (unknown), Xia Xu, Ingrid L. Scully, Daniel A. Scott, Kathrin U. Jansen, William C. Gruber, Wendy Watson	53
11	A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States 2021 ·Human Vaccines & Immunotherapeutics ·David Fitzpatrick, (unknown), Daniel A. Scott, Ingrid L. Scully, (unknown), Yahong Peng, Kathrin U. Jansen, William C. Gruber, Wendy Watson	9
12	Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence 2020 ·Human Vaccines & Immunotherapeutics ·(unknown), Daniel A. Scott, Beate Schmöele-Thoma, Wendy Watson, Mary M. Moran, Raúl Istúriz	8
13	3. Phase 3 Pivotal Evaluation of 20-valent Pneumococcal Conjugate Vaccine (PCV20) Safety, Tolerability, and Immunologic Noninferiority in Participants 18 Years and Older 2020 ·Open Forum Infectious Diseases ·Brandon Essink, Charu Sabharwal, Xia Xu, Vani Sundaraiyer, Yahong Peng, (unknown), Michael W. Pride, Ingrid L. Scully, Kathrin U. Jansen, William C. Gruber, Daniel A. Scott, Wendy Watson	10
14	Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults 2019 ·Vaccine ·Allison Thompson, (unknown), Joseph M. Severs, Ingrid L. Scully, Sanela Tarabar, John Ginis, Kathrin U. Jansen, William C. Gruber, Daniel A. Scott, Wendy Watson	77
15	Decreased complexity of glucose dynamics in diabetes in rhesus monkeys 2019 ·Scientific Reports ·Richard F. Raubertas, (unknown), Wendy Watson, Steven V. Fox, (unknown), (unknown), Ashleigh Bone, (unknown), Liza Gantert, Stacey Conarello, Walter Knapp, (unknown), (unknown), (unknown)	1
16	Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial 2018 ·Human Vaccines & Immunotherapeutics ·Allison Thompson, Nicola P. Klein, H. Jackson Downey, Scott D. Patterson, Vani Sundaraiyer, Wendy Watson, (unknown), Kathrin U. Jansen, Shite Sebastian, William C. Gruber, Daniel A. Scott, Beate Schmöele-Thoma	16
17	Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations 2018 ·Human Vaccines & Immunotherapeutics ·Christine Juergens, James Trammel, Yasuko Shoji, Scott D. Patterson, Wendy Watson, Chris Webber, William C. Gruber, Daniel A. Scott, Beate Schmöele-Thoma	4
18	Pathways to preterm birth: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data 2016 ·Vaccine ·Margo S. Harrison, Linda O. Eckert, Clare Cutland, Michael G. Gravett, Diane M. Harper, Elizabeth M. McClure, Anthony P. Nunes, (unknown), Tamala Mallett Moore, Wendy Watson, Sonali Kochhar, Robert L. Goldenberg	15
19	Preterm birth: Case definition & guidelines for data collection, analysis, and presentation of immunisation safety data breakdown → 2016 ·Vaccine ·(unknown), Flor M. Muñoz, Bernard Gonik, (unknown), Clare Cutland, Tamala Mallett Moore, Aimée Kissou, Frederick Wittke, Manoja Kumar Das, (unknown), (unknown), Wendy Watson, (unknown), José F. Cordero, Wan‐Ting Huang, Sonali Kochhar, Jim Buttery	300
20	Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children breakdown → 2000 ·The Pediatric Infectious Disease Journal ·Steven Black, Henry R. Shinefield, Bruce Fireman, Edwin Lewis, Paula Ray, John Hansen, (unknown), Kathleen Ensor, Jill Hackell, George R. Siber, Frank Malinoski, Dace V. Madore, Ih Chang, Robert Kohberger, Wendy Watson, Robert Austrian, Kathryn M. Edwards	1817

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact